Summary
Edwards Lifesciences Corporation (EW) reported its first quarter results for the period ending March 31, 2010. The company demonstrated solid top-line growth, with net sales increasing by 8.6% to $340.5 million compared to the prior year period. This growth was primarily driven by strong performance in the Heart Valve Therapy segment, which saw a 15.4% increase in net sales, notably from the Edwards SAPIEN transcatheter heart valve and the Carpentier-Edwards PERIMOUNT Magna Ease valve. While the company saw an increase in net sales, profitability experienced a decrease. Net income for the quarter was $47.7 million, or $0.80 per diluted share, down from $60.5 million, or $1.03 per diluted share, in the same period last year. This decline in net income is largely attributable to the absence of significant special gains that boosted the prior year's results, along with increased investments in research and development and higher selling, general, and administrative expenses. Investors should monitor the company's ability to translate revenue growth into improved profitability and keep an eye on the ongoing clinical trials and product launches, particularly in the transcatheter heart valve space.
Financial Highlights
25 data points| Revenue | $340.50M |
| Cost of Revenue | $98.60M |
| Gross Profit | $241.90M |
| R&D Expenses | $45.20M |
| SG&A Expenses | $134.00M |
| Net Income | $47.70M |
| EPS (Basic) | $0.07 |
| EPS (Diluted) | $0.07 |
| Shares Outstanding (Basic) | 679.20M |
| Shares Outstanding (Diluted) | 714.00M |
Key Highlights
- 1Net sales increased by 8.6% to $340.5 million, driven by strong performance in Heart Valve Therapy.
- 2Heart Valve Therapy segment sales grew by 15.4% to $196.7 million, supported by the Edwards SAPIEN and Carpentier-Edwards PERIMOUNT Magna Ease valves.
- 3Net income decreased to $47.7 million ($0.80 per diluted share) from $60.5 million ($1.03 per diluted share) year-over-year, impacted by the absence of prior-year special gains.
- 4Research and development expenses increased to $45.2 million, reflecting investments in transcatheter and surgical heart valve programs.
- 5Selling, general, and administrative (SG&A) expenses rose to $134.0 million, partly due to foreign currency fluctuations and increased sales support for transcatheter heart valve products.
- 6The company is advancing its transcatheter aortic valve replacement (TAVR) program, with the Edwards SAPIEN XT receiving CE Mark and progressing through clinical trials.
- 7Edwards Lifesciences repurchased $98.0 million of its common stock during the quarter, completing its previous authorization and initiating a new $500 million repurchase program.